SPECC1L and neoplasm: To date, responses to ALKi in two NSCLC patients with different SPECC1L-AL fusion variants have been published only in one previous work, and the clinical outcome of the patients supports the idea that SPECC1L may be a tumor driver factor that can be inhibited by a series of TKIs [7].